Broader adoption of MUSE strengthens Medigus' growth potential in Europe following completion of several procedures in leading healthcare institutions
Code Represents Important First Step In Process To Gain Coverage For Incisionless Procedures To Treat The Underlying Cause Of GERD.
Final Code Scheduled to Take Effect January 2016
CEO Chris Rowland Scheduled to Present on March 11, 2015 at 10:00 a.m. PDT
New agreement represents at least $17.6 million over four years, following CFDA approval.
Medigus To Present Data on MUSE™ Combined with Peroral Treatment of Achalasia At United European Gastroenterology Week 2014
85% of patients reduced medication use following the MUSE™ minimally-invasive procedure with 65% of them eliminating medication entirely after 6 months.
Link to publication on PubMed
Medigus Announces Signing Of $11.1 Million Private Placement.
New MUSE™ System Features Significant Technological Improvements, Including Enhanced User Interface and Software Control. Company to Launch MUSE™ System At U.S. Centers of Excellence -
Medigus (TASE:MDGS) completed a public issuance of shares and options in the total amount of NIS 24.8 million
Medigus Ltd. (MDGS.TA) announced today the presentation of five-year follow-up data on a pilot study of its FDA-cleared (510K) SRS™ Surgical Stapler for the treatment of GERD at the 2013 United European Gastroenterology’s (UEG) Week in Berlin.
Israel - September 11, 2013
Medigus Announces the Receipt of Approval from the Israeli Ministry of Health (MEA) for the Marketing of SRS™ Systems for the Treatment of Gastroesophageal Reflux Disease (GERD). The receipt of approval is expected to expedite regulatory approvals in other countries, including approval from the regulatory authorities in China (SFDA)
Medigus (TASE:MDGS) announces that it had closed an $8 million investment by OrbiMed Israel Partners LP. Upon the closing of the investment, Dr. Nissim Darvish, senior managing director at OrbiMed Israel, was appointed chairman of the board of directors of Medigus.